{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T19:11:38Z","timestamp":1792696298814,"version":"4.5.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Genome Med"],"DOI":"10.1186\/s13073-025-01499-5","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T11:19:46Z","timestamp":1751368786000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Understanding how gene-disease relationships can impact clinical utility: adaptations and challenges in hereditary cancer testing"],"prefix":"10.1186","volume":"17","author":[{"given":"Jennifer","family":"Herrera-Mullar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn","family":"Horton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amybeth","family":"Weaver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghan","family":"Towne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer M.","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace E.","family":"VanNoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven M.","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bess","family":"Wayburn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,1]]},"reference":[{"issue":"1","key":"1499_CR1","doi-asserted-by":"publisher","first-page":"103","DOI":"10.6004\/jnccn.2020.7674","volume":"19","author":"R Pilarski","year":"2021","unstructured":"Pilarski R. How Have Multigene Panels Changed the Clinical Practice of Genetic Counseling and Testing. J Natl Compr Canc Netw. 2021;19(1):103\u20138. https:\/\/doi.org\/10.6004\/jnccn.2020.7674.","journal-title":"J Natl Compr Canc Netw"},{"key":"1499_CR2","unstructured":"National Comprehensive Cancer Network. Genetic\/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic. Version 3.2023. Accessed August 2, 2023. To view the most recent version, visit NCCN.org."},{"issue":"4","key":"1499_CR3","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1007\/s10897-014-9695-6","volume":"23","author":"S Hiraki","year":"2014","unstructured":"Hiraki S, Rinella ES, Schnabel F, Oratz R, Ostrer H. Cancer risk assessment using genetic panel testing: considerations for clinical application. J Genet Couns. 2014Aug;23(4):604\u201317. https:\/\/doi.org\/10.1007\/s10897-014-9695-6.","journal-title":"J Genet Couns"},{"key":"1499_CR4","doi-asserted-by":"crossref","unstructured":"Grissom AA, Friend PJ. Multigene Panel Testing for Hereditary Cancer Risk. J Adv Pract Oncol. 2016 May-Jun;7(4):394\u2013407. Epub 2016 May 1. PMID: 29225998; PMCID: PMC5679029","DOI":"10.6004\/jadpro.2016.7.4.3"},{"key":"1499_CR5","doi-asserted-by":"publisher","unstructured":"Wilcox N, Dumont M, Gonz\u00e1lez-Neira A, Carvalho S, Joly Beauparlant C, Crotti M, Luccarini C, Soucy P, Dubois S, Nu\u00f1ez-Torres R, Pita G, et al. Exome sequencing identifies breast cancer susceptibility genes and defines the contribution of coding variants to breast cancer risk. Nat Genet. 2023 Sep;55(9):1435\u20131439. https:\/\/doi.org\/10.1038\/s41588-023-01466-z. Epub 2023 Aug 17. Erratum in: Nat Genet. 2023 Nov;55(11):2009. https:\/\/doi.org\/10.1038\/s41588-023-01549-x.","DOI":"10.1038\/s41588-023-01466-z"},{"issue":"4","key":"1499_CR6","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1016\/j.ajhg.2023.03.002","volume":"110","author":"C Cybulski","year":"2023","unstructured":"Cybulski C, Zamani N, Klu\u017aniak W, Milano L, Woko\u0142orczyk D, Stempa K, Rudnicka H, Zhang S, Zadeh M, Huzarski T, et al. Variants in ATRIP are associated with breast cancer susceptibility in the Polish population and UK Biobank. Am J Hum Genet. 2023;110(4):648\u201362. https:\/\/doi.org\/10.1016\/j.ajhg.2023.03.002. Epub 2023 Mar 27.","journal-title":"Am J Hum Genet"},{"key":"1499_CR7","unstructured":"Ivarsdottir EV, Gudmundsson J, Tragante V, Sveinbjornsson G, Kristmundsdottir S, Stacey SN, ... Stefansson K. (2024). Gene-based burden tests of rare germline variants identify six cancer susceptibility genes.\u00a0Nature Genetics. 1\u201312. https:\/\/www.nature.com\/articles\/s41588-024-01966-6."},{"issue":"5","key":"1499_CR8","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1002\/humu.23183","volume":"38","author":"ED Smith","year":"2017","unstructured":"Smith ED, Radtke K, Rossi M, Shinde DN, Darabi S, El-Khechen D, Powis Z, Helbig K, Waller K, Grange DK, Tang S, Farwell Hagman KD. Classification of Genes: Standardized Clinical Validity Assessment of Gene-Disease Associations Aids Diagnostic Exome Analysis and Reclassifications. Hum Mutat. 2017May;38(5):600\u20138. https:\/\/doi.org\/10.1002\/humu.23183.","journal-title":"Hum Mutat"},{"issue":"6","key":"1499_CR9","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/j.ajhg.2017.04.015","volume":"100","author":"NT Strande","year":"2017","unstructured":"Strande NT, Riggs ER, Buchanan AH, Ceyhan-Birsoy O, DiStefano M, Dwight SS, Goldstein J, Ghosh R, Seifert BA, Sneddon TP, et al. Evaluating the Clinical Validity of Gene-Disease Associations: An Evidence-Based Framework Developed by the Clinical Genome Resource. Am J Hum Genet. 2017Jun 1;100(6):895\u2013906. https:\/\/doi.org\/10.1016\/j.ajhg.2017.04.015.","journal-title":"Am J Hum Genet"},{"key":"1499_CR10","unstructured":"Variant Pathogenicity Curation Documents. The Clinical Genome Resource [accessed June 7, 2024] available at: https:\/\/www.clinicalgenome.org\/curation-activities\/variant-pathogenicity\/documents\/."},{"key":"1499_CR11","unstructured":"Gene-Disease Clinical Validity Documents. The clinical genome resource. [accessed June 7, 2024] available at: https:\/\/clinicalgenome.org\/curation-activities\/gene-disease-validity\/documents\/."},{"key":"1499_CR12","doi-asserted-by":"crossref","unstructured":"Thaxton C, Good ME, DiStefano MT, et al. Clingen gene curation working group; clingen dosage sensitivity working group. utilizing clingen gene-disease validity and dosage sensitivity curations to inform variant classification. Hum Mutat. 2022;43(8):1031\u20131040. https:\/\/doi.org\/10.1002\/humu.24291.","DOI":"10.1002\/humu.24291"},{"key":"1499_CR13","doi-asserted-by":"publisher","unstructured":"Bean LJH, Funke B, Carlston CM, Gannon JL, Kantarci S, Krock BL, Zhang S, Bayrak-Toydemir P. ACMG laboratory quality assurance committee. diagnostic gene sequencing panels: from design to report-a technical standard of the american college of medical genetics and genomics (ACMG). Genet Med. 2020;22(3):453\u2013461. https:\/\/doi.org\/10.1038\/s41436-019-0666-z. Epub 2019 Nov 16. PMID: 31732716.","DOI":"10.1038\/s41436-019-0666-z"},{"key":"1499_CR14","doi-asserted-by":"crossref","unstructured":"Tung N, Ricker C, Messersmith H, Balma\u00f1a J, Domchek S, Stoffel EM, Almhanna K, Arun B, Chavarri-Guerra Y, Cohen SA, et al. Selection of Germline Genetic Testing Panels in Patients With Cancer: ASCO Guideline. J Clin Oncol. 2024;JCO2400662. https:\/\/doi.org\/10.1200\/JCO.24.00662.","DOI":"10.1200\/JCO.24.00662"},{"issue":"8","key":"1499_CR15","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1111\/tbj.13971","volume":"26","author":"S Reid","year":"2020","unstructured":"Reid S, Pal T. Update on multi-gene panel testing and communication of genetic test results. Breast J. 2020Aug;26(8):1513\u20139. https:\/\/doi.org\/10.1111\/tbj.13971.","journal-title":"Breast J"},{"issue":"20","key":"1499_CR16","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1200\/JCO.2016.71.6480","volume":"35","author":"AW Kurian","year":"2017","unstructured":"Kurian AW, Li Y, Hamilton AS, Ward KC, Hawley ST, Morrow M, McLeod MC, Jagsi R, Katz SJ. Gaps in Incorporating germline genetic testing into treatment decision-making for early-stage breast cancer. J Clin Oncol. 2017;35(20):2232\u20139. https:\/\/doi.org\/10.1200\/JCO.2016.71.6480.","journal-title":"J Clin Oncol."},{"issue":"11","key":"1499_CR17","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1002\/humu.23604","volume":"39","author":"JL McGlaughon","year":"2018","unstructured":"McGlaughon JL, Goldstein JL, Thaxton C, Hemphill SE, Berg JS. The progression of the ClinGen gene clinical validity classification over time. Hum Mutat. 2018Nov;39(11):1494\u2013504. https:\/\/doi.org\/10.1002\/humu.23604.","journal-title":"Hum Mutat"},{"issue":"5","key":"1499_CR18","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde M, Lyon E, Spector E, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015May;17(5):405\u201324. https:\/\/doi.org\/10.1038\/gim.2015.30.","journal-title":"Genet Med"},{"issue":"4","key":"1499_CR19","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1002\/ijc.23168","volume":"122","author":"N Bogdanova","year":"2008","unstructured":"Bogdanova N, Feshchenko S, Sch\u00fcrmann P, Waltes R, Wieland B, Hillemanns P, Rogov YI, Dammann O, Bremer M, Karstens JH, Sohn C, Varon R, D\u00f6rk T. Nijmegen Breakage Syndrome mutations and risk of breast cancer. Int J Cancer. 2008Feb 15;122(4):802\u20136. https:\/\/doi.org\/10.1002\/ijc.23168. (PMID: 17957789).","journal-title":"Int J Cancer"},{"issue":"23","key":"1499_CR20","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1056\/NEJMsr1501341","volume":"372","author":"DF Easton","year":"2015","unstructured":"Easton DF, Pharoah PD, Antoniou AC, Tischkowitz M, Tavtigian SV, Nathanson KL, Devilee P, Meindl A, Couch FJ, Southey M, Goldgar DE, Evans DG, Chenevix-Trench G, Rahman N, Robson M, Domchek SM, Foulkes WD. Gene-panel sequencing and the prediction of breast-cancer risk. N Engl J Med. 2015Jun 4;372(23):2243\u201357. https:\/\/doi.org\/10.1056\/NEJMsr1501341.","journal-title":"N Engl J Med"},{"issue":"11","key":"1499_CR21","doi-asserted-by":"publisher","first-page":"5832","DOI":"10.3390\/ijms22115832","volume":"22","author":"R Zuntini","year":"2021","unstructured":"Zuntini R, Bonora E, Pradella LM, Amato LB, Vidone M, De Fanti S, Catucci I, Cortesi L, Medici V, Ferrari S, et al. Detecting Variants in the NBN Gene While Testing for Hereditary Breast Cancer: What to Do Next? Int J Mol Sci. 2021May 29;22(11):5832. https:\/\/doi.org\/10.3390\/ijms22115832.","journal-title":"Int J Mol Sci"},{"issue":"9","key":"1499_CR22","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1001\/jamaoncol.2017.0424","volume":"3","author":"FJ Couch","year":"2017","unstructured":"Couch FJ, Shimelis H, Hu C, Hart SN, Polley EC, Na J, Hallberg E, Moore R, Thomas A, Lilyquist J, et al. Associations Between Cancer Predisposition Testing Panel Genes and Breast Cancer. JAMA Oncol. 2017Sep 1;3(9):1190\u20136. https:\/\/doi.org\/10.1001\/jamaoncol.2017.0424.","journal-title":"JAMA Oncol"},{"issue":"5","key":"1499_CR23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1005228","volume":"11","author":"J Sun","year":"2015","unstructured":"Sun J, Wang Y, Xia Y, Xu Y, Ouyang T, Li J, Wang T, Fan Z, Fan T, Lin B, et al. Mutations in RECQL Gene Are Associated with Predisposition to Breast Cancer. PLoS Genet. 2015May 6;11(5): e1005228. https:\/\/doi.org\/10.1371\/journal.pgen.1005228.","journal-title":"PLoS Genet"},{"issue":"6","key":"1499_CR24","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1038\/ng.3284","volume":"47","author":"C Cybulski","year":"2015","unstructured":"Cybulski C, Carrot-Zhang J, Klu\u017aniak W, Rivera B, Kashyap A, Woko\u0142orczyk D, Giroux S, Nadaf J, Hamel N, Zhang S, et al. Germline RECQL mutations are associated with breast cancer susceptibility. Nat Genet. 2015Jun;47(6):643\u20136. https:\/\/doi.org\/10.1038\/ng.3284.","journal-title":"Nat Genet"},{"issue":"11","key":"1499_CR25","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1038\/ejhg.2014.16","volume":"22","author":"L Cast\u00e9ra","year":"2014","unstructured":"Cast\u00e9ra L, Krieger S, Rousselin A, Legros A, Baumann JJ, Bruet O, Brault B, Fouillet R, Goardon N, Letac O, et al. Next-generation sequencing for the diagnosis of hereditary breast and ovarian cancer using genomic capture targeting multiple candidate genes. Eur J Hum Genet. 2014Nov;22(11):1305\u201313. https:\/\/doi.org\/10.1038\/ejhg.2014.16.","journal-title":"Eur J Hum Genet"},{"issue":"5","key":"1499_CR26","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1002\/mgg3.157","volume":"3","author":"Y Hirotsu","year":"2015","unstructured":"Hirotsu Y, Nakagomi H, Sakamoto I, Amemiya K, Oyama T, Mochizuki H, Omata M. Multigene panel analysis identified germline mutations of DNA repair genes in breast and ovarian cancer. Mol Genet Genomic Med. 2015Sep;3(5):459\u201366. https:\/\/doi.org\/10.1002\/mgg3.157.","journal-title":"Mol Genet Genomic Med"},{"key":"1499_CR27","doi-asserted-by":"crossref","unstructured":"Thompson ER, Doyle MA, Ryland GL, Rowley SM, Choong DY, Tothill RW, Thorne H, kConFab, Barnes DR, Li J, et al. Exome sequencing identifies rare deleterious mutations in DNA repair genes FANCC and BLM as potential breast cancer susceptibility alleles. PLoS Genet. 2012;8(9):e1002894. https:\/\/doi.org\/10.1371\/journal.pgen.1002894.","DOI":"10.1371\/journal.pgen.1002894"},{"issue":"20","key":"1499_CR28","doi-asserted-by":"publisher","first-page":"6113","DOI":"10.1158\/1078-0432.CCR-16-3227","volume":"23","author":"J Sun","year":"2017","unstructured":"Sun J, Meng H, Yao L, Lv M, Bai J, Zhang J, Wang L, Ouyang T, Li J, Wang T, et al. Germline Mutations in Cancer Susceptibility Genes in a Large Series of Unselected Breast Cancer Patients. Clin Cancer Res. 2017Oct 15;23(20):6113\u20139. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-3227.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"1499_CR29","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1002\/ijc.11231","volume":"106","author":"B G\u00f3rski","year":"2003","unstructured":"G\u00f3rski B, Debniak T, Masoj\u0107 B, et al. Germline 657del5 mutation in the NBS1 gene in breast cancer patients. Int J Cancer. 2003Sep 1;106(3):379\u201381. https:\/\/doi.org\/10.1002\/ijc.11231.","journal-title":"Int J Cancer"},{"issue":"2","key":"1499_CR30","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1002\/ijc.21853","volume":"119","author":"J Steffen","year":"2006","unstructured":"Steffen J, Nowakowska D, Niwi\u0144ska A, Czapczak D, Kluska A, Piatkowska M, Wi\u015bniewska A, Paszko Z. Germline mutations 657del5 of the NBS1 gene contribute significantly to the incidence of breast cancer in Central Poland. Int J Cancer. 2006Jul 15;119(2):472\u20135. https:\/\/doi.org\/10.1002\/ijc.21853.","journal-title":"Int J Cancer"},{"issue":"5","key":"1499_CR31","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.1007\/s13277-013-0830-z","volume":"34","author":"G Zhang","year":"2013","unstructured":"Zhang G, Zeng Y, Liu Z, Wei W. Significant association between Nijmegen breakage syndrome 1 657del5 polymorphism and breast cancer risk. Tumour Biol. 2013Oct;34(5):2753\u20137. https:\/\/doi.org\/10.1007\/s13277-013-0830-z.","journal-title":"Tumour Biol"},{"key":"1499_CR32","doi-asserted-by":"crossref","unstructured":"Gradishar WJ, Anderson BO, Balassanian R, Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A, Giordano SH, et al. NCCN Guidelines Insights: Breast Cancer, Version 1.2017. J Natl Compr Canc Netw. 2017;15(4):433\u2013451. Retrieved Jun 7, 2024, from https:\/\/doi.org\/10.6004\/jnccn.2017.0044.\u00a0","DOI":"10.6004\/jnccn.2017.0044"},{"issue":"1","key":"1499_CR33","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s13073-022-01052-8","volume":"14","author":"L Dorling","year":"2022","unstructured":"Dorling L, Carvalho S, Allen J, Parsons MT, Fortuno C, Gonz\u00e1lez-Neira A, Heijl SM, Adank MA, Ahearn TU, Andrulis IL, et al. Breast cancer risks associated with missense variants in breast cancer susceptibility genes. Genome Med. 2022May 18;14(1):51. https:\/\/doi.org\/10.1186\/s13073-022-01052-8.","journal-title":"Genome Med"},{"issue":"5","key":"1499_CR34","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1056\/NEJMoa2005936","volume":"384","author":"C Hu","year":"2021","unstructured":"Hu C, Hart SN, Gnanaolivu R, Huang H, Lee KY, Na J, Gao C, Lilyquist J, Yadav S, Boddicker NJ, et al. A Population-Based Study of Genes Previously Implicated in Breast Cancer. N Engl J Med. 2021Feb 4;384(5):440\u201351. https:\/\/doi.org\/10.1056\/NEJMoa2005936.","journal-title":"N Engl J Med"},{"issue":"12","key":"1499_CR35","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1136\/jmedgenet-2020-107140","volume":"58","author":"E Tudini","year":"2021","unstructured":"Tudini E, Davidson AL, Dressel U, Andrews L, Antill Y, Crook A, Field M, Gattas M, Harris R, Kirk J, et al. Implementing gene curation for hereditary cancer susceptibility in Australia: achieving consensus on genes with clinical utility. J Med Genet. 2021Dec;58(12):853\u20138. https:\/\/doi.org\/10.1136\/jmedgenet-2020-107140.","journal-title":"J Med Genet"},{"issue":"7","key":"1499_CR36","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1038\/s41436-018-0361-5","volume":"21","author":"K Lee","year":"2019","unstructured":"Lee K, Seifert BA, Shimelis H, Ghosh R, Crowley SB, Carter NJ, Doonanco K, Foreman AK, Ritter DI, Jimenez S, et al. Clinical validity assessment of genes frequently tested on hereditary breast and ovarian cancer susceptibility sequencing panels. Genet Med. 2019Jul;21(7):1497\u2013506. https:\/\/doi.org\/10.1038\/s41436-018-0361-5.","journal-title":"Genet Med"},{"key":"1499_CR37","doi-asserted-by":"publisher","unstructured":"Kurian AW, Ford JM. Multigene Panel testing in oncology practice: how should we respond? JAMA Oncol. 2015;1(3):277\u2013278. https:\/\/doi.org\/10.1001\/jamaoncol.2015.28","DOI":"10.1001\/jamaoncol.2015.28"},{"key":"1499_CR38","doi-asserted-by":"crossref","unstructured":"Chiang J, Chia TH, Yuen J, Shaw T, Li ST, Binte Ishak ND, Chew EL, Chong ST, Chan SH, Ngeow J. Impact of variant reclassification in cancer predisposition genes on clinical care. JCO Precis Oncol. 2021;5:577\u2013584. https:\/\/doi.org10.1200\/PO.20.00399.","DOI":"10.1200\/PO.20.00399"},{"key":"1499_CR39","doi-asserted-by":"publisher","unstructured":"Mersch J, Brown N, Pirzadeh-Miller S, Mundt E, Cox HC, Brown K, Aston M, Esterling L, Manley S, Ross T. Prevalence of Variant Reclassification Following Hereditary Cancer Genetic Testing. JAMA. 2018;320(12):1266\u20131274.\u00a0https:\/\/doi.org\/10.1001\/jama.2018.13152.","DOI":"10.1001\/jama.2018.13152"},{"issue":"3","key":"1499_CR40","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/gim.2017.207","volume":"20","author":"S Macklin","year":"2018","unstructured":"Macklin S, Durand N, Atwal P, Hines S. Observed frequency and challenges of variant reclassification in a hereditary cancer clinic. Genet Med. 2018Mar;20(3):346\u201350. https:\/\/doi.org\/10.1038\/gim.2017.207.","journal-title":"Genet Med"},{"key":"1499_CR41","doi-asserted-by":"publisher","unstructured":"Gould D, Walker R, Makari-Judson G, Seven M. Experiences of individuals with a variant of uncertain significance on genetic testing for hereditary cancer risks: a mixed method systematic review. J Community Genet. 2022;13(4):371\u2013379. https:\/\/doi.org\/10.1007\/s12687-022-00600-4.","DOI":"10.1007\/s12687-022-00600-4"},{"issue":"4","key":"1499_CR42","doi-asserted-by":"publisher","first-page":"iyad121","DOI":"10.1093\/genetics\/iyad121","volume":"224","author":"P Hieter","year":"2023","unstructured":"Hieter P, Andrews B, Fowler D, Bellen H. Highlighting rare disease research with a GENETICS and G3 series on genetic models of rare diseases. Genetics. 2023;224(4):iyad121. https:\/\/doi.org\/10.1093\/genetics\/iyad121.","journal-title":"Genetics."},{"issue":"3","key":"1499_CR43","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/j.mehy.2007.01.050","volume":"69","author":"F Eisinger","year":"2007","unstructured":"Eisinger F, Horsman D. Hereditary cancer gene hunting.\u00a0A phase of declining success? Med Hypotheses. 2007;69(3):690\u20132. https:\/\/doi.org\/10.1016\/j.mehy.2007.01.050.","journal-title":"Med Hypotheses."},{"issue":"9","key":"1499_CR44","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1002\/humu.23017","volume":"37","author":"MR Chandler","year":"2016","unstructured":"Chandler MR, Bilgili EP, Merner ND. A Review of Whole-Exome Sequencing Efforts Toward Hereditary Breast Cancer Susceptibility Gene Discovery. Hum Mutat. 2016S;37(9):835\u201346. https:\/\/doi.org\/10.1002\/humu.23017.","journal-title":"Hum Mutat"},{"issue":"22","key":"1499_CR45","doi-asserted-by":"publisher","first-page":"8757","DOI":"10.3390\/ijms21228757","volume":"21","author":"IBAW Te Paske","year":"2020","unstructured":"Te Paske IBAW, Ligtenberg MJL, Hoogerbrugge N, de Voer RM. Candidate Gene Discovery in Hereditary Colorectal Cancer and Polyposis Syndromes-Considerations for Future Studies. Int J Mol Sci. 2020N 19;21(22):8757. https:\/\/doi.org\/10.3390\/ijms21228757.","journal-title":"Int J Mol Sci"}],"container-title":["Genome Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13073-025-01499-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13073-025-01499-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13073-025-01499-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T11:19:49Z","timestamp":1751368789000},"score":1,"resource":{"primary":{"URL":"https:\/\/genomemedicine.biomedcentral.com\/articles\/10.1186\/s13073-025-01499-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1499"],"URL":"https:\/\/doi.org\/10.1186\/s13073-025-01499-5","relation":{},"ISSN":["1756-994X"],"issn-type":[{"value":"1756-994X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,1]]},"assertion":[{"value":"19 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"WCG Institutional Review Board determined the study to be exempt from the Office for Human Research Protections Regulations for the Protection of Human Subjects (45 CFR 46) under category 4. Retrospective data analysis of de-identified data exempted the study from the requirement to receive consent from patients. We confirm that this research conforms to the principles of the Helsinki Declaration.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate."}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors are employees of Ambry Genetics Corporation at the time of submission.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"73"}}